NeoCanna Technologies Inc.
(NCTI) presents:
NeoCanna
The New Standard In CBD Delivery
THE WORLD’S FIRST & ONLY
24 Hour Time Release CBD Tablets
Standardized Water-Soluble Cannabidiol
Matthew Hay, President & COO
NeoCanna Technologies, Inc.
4155 E Jewell Avenue, Suite 709
Denver, Colorado, USA, 80222
778-215-6288
[email protected]
This document is non-confidential. Please share, and recycle.
Who We Are
Rick Stewart – CEO
Mr. Stewart has over 20 years of experience in developing, formulating,
manufacturing, marketing and distributing pharmaceuticals and nutraceuticals
to the human and veterinary markets. He was the originator of the LaKOTA
brand, which he built to 35 million in revenues within 24 months. He sold his
interest in LaKOTA in order to acquire the Liniex 24 Hour Delivery Technology,
which he has incorporated into his new supplement line (Chrono Health Care).
Mr. Stewart, along with his vast industry experience, brings the revolutionary Liniex
24 Hour Delivery Technology to NeoCanna, in the form of the global supplement
rights for cannabis.
Rick Robinson – Chairman
Mr. Robinson has worked over forty years in the executive oversight, engineering,
procurement and construction of major energy projects on a global scale,
where he oversaw construction budgets in the tens of billions and provided
direction to his teams to deliver against safety, schedule, cost and quality
objectives. In addition to NeoCanna, Mr. Robinson resides as Chairman of two
technology companies associated with green power generation and green
mineral processing.
Education: Bachelor of Science, Civil Engineering, University of California. Masters
in Civil Engineering, Stanford University
Matthew Hay - President and COO
Mr. Hay has over twenty years of experience in resource and business
development sectors, working for some of the largest EPC firms. Some of Mr.
Hay’s global interactions and responsibilities have included vendor/supplier
relationships, manufacturing, logistics, IT, infrastructure, temporary foreign
workers, human resources, finance, construction and engineering/design. In
addition, he has extensive start-up and project management in real estate
development, construction and business management, for which he has won
awards.
Education: Bachelor of Science, University of Alberta
Problems/Solutions
1) Standardized Dosing
A lack of standardized dosing represents one of the largest gaps in the industry.
Combine this with the recent consumer reports about ingredient ‘pixiedusting’, ‘snake oil’ or ‘less than advertised’ ingredient amounts, and consumers
are looking for a CBD source they can trust, both in its quality and quantity.
NeoCanna addresses these concerns by using a 99%+ pure, pharma grade,
water-soluble CBD powder of the highest quality. This ensures that an exact
amount of CBD is in every one of our tablets.
NeoCanna will become a name in the CBD space that can and will be trusted,
through transparency, dependability and quality.
2) Peaks and Valleys – Liniex 24 Hour Delivery Technology
Ingesting most ingredients creates a Peak and Valley trajectory in the body.
When the coating of the capsule or tablet is dissolved in the stomach, it results in
a large spike of the ingredient.
The body can only process a certain amount of ingredient at any given time.
Within a few hours, the ingredient is naturally excreted. This leaves the body
without any active ingredient on board for the remainder of the day.
What makes us different from anyone else in the market is our patented Liniex 24
Hour Delivery Technology, which delivers our CBD consistently, all day and night,
with a single daily dose.
Customers will appreciate this concept and adopt our delivery technology as
the ‘New Standard in CBD Delivery’.
This is arguably the single biggest differentiator and advancement in this space,
and will pave the way for an expanded new frontier of nutrient delivery and true
human health.
3) Cost/Value Add
Having to re-dose throughout the day to maintain CBD levels can be expensive,
inefficient and inconvenient. NeoCanna products eliminate this requirement.
A consumer would have to take multiple daily doses of any of our competitors in
order to achieve full 24-hour coverage of CBD in the body.
4) Bioavailability
Water-soluble CBD has a much greater bioavailability than the fat-soluble
products.
NeoCanna products take this one quantum leap further; by combining our
technology and the best water soluble CBD on the market.
Not only is our CBD water soluble, it has the unprecedented benefit of being
delivered to the body in small, consistent amounts, throughout the entire day
and night, making that water soluble CBD available for a dramatically
expanded time window (24 hours vs. a few hours).
5) Reaching Customers
NeoCanna is a direct to consumer, online sales platform.
Our marketing partner has created a proprietary algorithm and associated
marketing system.
Their algorithm searches the internet, based on any search criteria (i.e. ‘Where
do I buy CBD?’ or ‘What is the best CBD for me?’ etc.). The system then collects
and reports all social conversations taking place, in real time, and brings them
right to our desktop.
Our system allows us to respond directly to these posts with our marketing funnel.
We only deploy marketing resources to people who are actively looking for what
we are selling.
We select the best, most significant conversations, taking place in real time, and
respond to these ‘customers in waiting’ directly and instantly, when they are in
the buying frame of mind.
Additionally, our marketing partner has a list of over 100 million, double opted in,
US email addresses, which it will use to further explode our sales.
Our Product
NeoCanna Technologies Inc. - Product #1
$69.95 USD for a bottle of 30 Neo CBD 5mg Bi-layer Tablets, shipping is extra.
We have combined 1mg with a standard immediate release coating, which also
makes it easier to swallow, and 4 mg with our Liniex Technology.
When our tablet hits the stomach, the immediate release portion saturates the
receptors of the endocannabinoid system.
The balance of the 4 mg is released slowly and consistently over 24 hours, to
keep the receptors ‘topped up’ and ensures that our CBD is on board all day
and night, with a single daily dose.
Upcoming formulations include larger denominations of CBD, full plant profiles
and even formulations that include THC, in locations where no prescription for
THC is required (i.e. Colorado, Oregon, Washington, etc.).
Market Opportunity
“During a gold rush, it is a good time to be in the pick and shovel business.”
Mark Twain
Cannabis is the fastest growing industry in the United States.
The CBD supplementation market in the USA, and beyond, is growing
exponentially and will only increase as people come to understand the many
benefits of this molecule.
We are not, at launch, trying to convince consumers that they should take CBD,
we are simply targeting those who already do, and illustrating that our product is
the best option for their health.
Our opportunity to create meaningful formulations and products, for a wide
range of targeted uses, delivered via our Liniex Technology, is limited only by the
current ongoing research and demand…both of which will continue to grow into
the future. Liniex is the tool that can positively serve the entire industry.
Aspirational Targets Met
Early on in this venture our biggest aspirational target was to acquire the medical
rights to use Liniex Technology with cannabis products. We have achieved this
major milestone well in advance of when we expected, thanks to the strength of
our team and our management of this burgeoning company.
This development alone has dramatically increased the value of the company. It
has also provided a huge layer of risk mitigation. Should the unthinkable happen,
and the US classifies CBD as ‘medical’ and does not allow it to be sold as a
supplement, we simply move our formulations over to the medical side and
continue on.
With both medical rights and supplement rights to Liniex, every door is an open
one.
Aspirational Targets
We intend on acquiring an elegant, time-release technology for the pet market,
as it relates to cannabis derivatives. This technology operates in the 8-12 hour
range, which is congruent with the digestive system of most pets.
We intend on acquiring the rights to a CBD/Liniex food supplement technology.
These aspirational targets will be funded from sales or via subsequent external
raises.
The Big Picture
We looked into the dollar amount spent on drugs globally each year on
common ailments that scientific evidence shows CBD is effective against. These
include heart disease, cancer, sleep disorders, diabetes, rheumatoid arthritis,
multiple sclerosis, depression, osteoporosis, psoriasis, Alzheimer’s, and anxiety. This
figure will total over 500 billion annually by the end of the decade.
While NCTI makes no specific health claims in the effectiveness of our NeoCanna
product against the following ailments, we make references to relevant scientific
studies. The following are projections of the amount spent on medication
annually for various ailments, and links to at least one example of CBD’s
effectiveness on these ailments:
1. Heart Disease $187B by 2018.
 Cannabidiol, a nonpsychoactive Cannabis constituent, protects
against myocardial ischemic reperfusion injury. Link
2. Cancer $147B by 2018.
 "When cancer cells are subjected to cannabidiol, there is a literal
death of those cancer cells. And we actually know the reason. It
turns out there are a lot of receptors at the surface of cancer cells
that don't occur on normal cells. Luckily they're cannabinoid
receptors and so by putting cannabidiol into the system you can
kill the cancer cell. And it’s now mandatory that all patients
receiving bone marrow transplants be put on a cannabidiol
regimen after the transplant, in Israel, because of this. And it's
saving lives. Mortality went from 30% rate post surgical, to less than
5%. That's incredible.” Link
 The inhibitory effects of cannabidiol on systemic malignant tumors
Link
3. Sleep Disorders $76.7B by 2019.
 Cannabidiol, a constituent of Cannabis sativa, modulates sleep in
rats. Link
4. Diabetes $55.3B by 2017.
 On type one diabetes: “While there are beta cells present, that’s
called the honeymoon period, if you administer cannabidiol you
reverse the condition.”
On type two diabetes: “Number 2, the laboratory experiments and
process at the Hebrew University have been so successful with
regards to type 2 diabetes that Israel did a very unusual thing… the
results in the laboratory were so startling, we were literally given an
institutional review board approval, we’re about to start now this
type 2 diabetes human clinical work at the Hebrew University. Link
 Cannabidiol attenuates cardiac dysfunction, oxidative stress,
fibrosis, and inflammatory and cell death signaling pathways in
diabetic cardiomyopathy. Link
5. Rheumatoid Arthritis $38.5B by 2017.
 The nonpsychoactive cannabis constituent cannabidiol is an oral
anti-arthritic therapeutic in murine collagen-induced arthritis. Link
6. Multiple Sclerosis $18.3B by 2018.
 Cannabidiol provides long-lasting protection against the
deleterious effects of inflammation in a viral model of multiple
sclerosis: a role for A2A receptors. Link
7. Depression $13.5B by 2018.
 Antidepressant-like and anxiolytic-like effects of cannabidiol: a
chemical compound of Cannabis sativa. Link
8. Osteoporosis $8.9B by 2020.
 Cannabidiol, a Major Non-Psychotropic Cannabis Constituent
Enhances Fracture Healing and Stimulates Lysyl Hydroxylase Activity
in Osteoblasts. Link
9. Psoriasis $8.9B by 2018.
 Cannabinoids inhibit human keratinocyte proliferation through a
non-CB1/CB2 mechanism and have a potential therapeutic value
in the treatment of psoriasis. Link
10. Alzheimer’s $8.7B by 2018.
 Cannabidiol promotes amyloid precursor protein ubiquitination
and reduction of beta amyloid expression in SHSY5YAPP+ cells
through PPARγ involvement. Link
11. Anxiety $5.9B by 2017.
 Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug.
Link
12. Epilepsy $4.5B by 2019.
 Cannabidiol displays antiepileptiform and antiseizure properties in
vitro and in vivo. Link
The above markets will total over $500B annually before the end of this decade.
Fuller list of Ailments
The following is an excerpt that will soon be posted on our draft website, listing
ailments that have cannabidiol studies associated with them. As you can see,
the list is long. It is unprecedented in the history of medicine to have one
molecule work against so many ailments, providing an almost endless amount of
opportunity for NeoCanna, thanks to the fact we now own the supplement and
medical rights to Liniex 24 Hour Delivery Technology.
“Disclaimer: Though vast amounts of knowledge exists online regarding
Cannabidiol’s potential uses, FDA regulations prevent NeoCanna from linking
directly to it.
When you click on the links below, it will take you to a Google search window. If
the ailment you’re interested in learning more about is not listed below, simply go
to Google, type “cbd against (the ailment)” and see what comes up.’”
Acne
Diabetes
Neuro Degeneration
ADD and ADHD
Endocrine Disorders
Nausea
Addiction
Epilepsy and Seizures
Neuropathic Pain
AIDS
Fibromyalgia
Obesity
ALS
Glaucoma
OCD
Alzheimer’s
Heart Disease
Osteoporosis
Anorexia
Huntington’s
Parkinson’s
Antibiotic Resistance
Inflammation
Prion/Mad Cow Disease
Anxiety
Irritable Bowl Syndrome
PTSD
Atherosclerosis
Kidney Disease
Schizophrenia
Arthritis
Liver Disease
Sickle Cell Anemia
Asthma
Metabolic Syndrome
Skin Conditions
Autism
Migraine
Sleep Disorders
Bipolar
Mood Disorders
Spinal Cord Injury
Cancer
Motion Sickness
Stress
Colitis and Crohn’s
Disease
Multiple Sclerosis
Stroke and Traumatic
Brain Injury
Depression
Competition
Wanabrands and Cannabics Pharmaceuticals have joined together to form
Wanacaps. From Colorado, Wanacaps is the only other company we’ve found
with patented time-release technology for oral use, but their maximum release
time is 12 hours, and they need 20 mg’s to get there.
We can release 5mg’s over 24 hours, giving us a factor of 8 in superiority to
Wanacaps.
Action Plan
Put product into inventory. Launch online marketing campaign. Make sales.
Repeat.
We have added Dr. Zeid Mohamedali to our board, as Medical Director. He is a
doctor of Urology and Surgeon in Pt. Alberni, Vancouver Island.
We are also working with Dr. Mark Cooper in Colorado with respect to clinical
trials. He is a naturopathic doctor and is part of a network of over 50 doctors
that are interested in selling our product to their clients.
We are advancing the medical side of our new rights much faster than
anticipated.
After telling him about our product, Marc Emery, the “Prince of Pot” told us that
every dispensary in Canada would carry it. While we want to wait until the law is
more clear in Canada until we do business there, this is encouraging news from
the world leader in cannabis advocacy.
We will soon be in touch with dispensaries across the USA to sell our product.
While continuing to support our base business model we would quickly expand
our marketing into additional demographics, formulate our next product
offerings and bring them to market, penetrate another country, and more of the
same.
In addition to acting as advocates for cannabis based medicine and research,
NeoCanna will work with some doctors on a pro-bono basis in an attempt to
help their patients with our technology.
Results
Figure 1: Annual Financial Summary
This table reflects our Annual Financial Summary with only one product and only
in the United States.
What We Need
We have achieved sufficient investment for launch. Product is currently in
production. We are open to further investment, to the right, value added
partner. For each 100k investors will receive a 1% equity stake in NeoCanna.
We believe the 3 pillars of this company, standardization, delivery, and
proprietary algorithms will ensure success.
Strategic support and partnerships would add tremendous value opportunity
and sustainability in this space, with the prime value add translating into helping
more people.
Investor Exit Strategy
Based on our conservative sales trajectory, the investors’ equity position would
result in return of investment principle by the end of the second year. Dividends
will be paid bi-annually.
Our mid to long-term strategy as described above is to launch additional
products and to penetrate additional markets.
Our long-term exit strategy is buyout or IPO.
Q &A
Q: Are your products being distributed in Canada?
A: We are going to launch in the USA first where we can sell CBD in 50 states.
When the legality of selling CBD in Canada is more sorted out we will launch
there.
Q: What are the laws surrounding cannabidiol in China?
A: It is estimated to cost in the hundreds of thousands to get a product like
NeoCanna to be approved to be sold in China as a drug, and a year or two in
time, but because of the rise of diabetes in China, that market alone could
dwarf many others in the world. ISA Scientific is working hard to penetrate the
Chinese market, but they lack the patented technology we have.
China has recently made it much easier than it used to be for vitamins and
supplements to get approval, but it is unclear at this point if NeoCanna could sell
our product as a supplement in China.
Q: What IP protections do you have in place?
A: Our technology is patented in the US and patent pending in most of the rest
of the world.
Q: Water-soluble CBD is also being developed by many competitors. Can you
speak to that?
A: This is good for us, and CBD use in general, as it appears to be a superior
product, and this will increase our supply line. Our biggest differentiator is our 24
hour release, not water-soluble CBD.
Q: How was your CBD source tested?
A: Our raw material comes from a Pharma Grade certified supplier. They use a
four-stage extraction process. The material is independently tested and we have
full track and trace on the source (organic industrial hemp, from seed and stalk.)
The company we source from is fully certified. We then independently test the
product when it arrives at our facility, to ensure accuracy.